Ticagrelor vs clopidogrel after stent for higher-risk heart patients
Part of Heart & circulation clinical trials.
This study compares two blood-thinning medicines—ticagrelor and clopidogrel—after you’ve already had a drug-eluting stent placed for a heart attack. It aims to see which option better prevents new heart-related events in people at higher risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 50 or older
- You had a drug-eluting stent placed for an acute heart attack 12 to 24 months ago
- You have at least one “high-risk” feature such as: age over 65, diabetes treatment, multi-vessel heart disease, more than two heart attacks, or kidney disease (stage III/IV)
- You are under age 85
- You can understand and read the informed consent form
- You do not need long-term anticoagulation (another long-term blood thinner)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two blood-thinning medicines—clopidogrel and aspirin—after you have finished a short period of dual therapy following a special type of drug-eluting heart stent. It may help find which medicine works better and is safer for preventing future heart problems.
This trial tests whether tailoring anti-platelet (blood clot prevention) treatment can better protect people at higher risk of heart or blood-vessel problems after a drug-eluting stent. It may help prevent future clots and complications, especially in patients with certain high-risk health conditions or complex stent/scar tissue features.
This study compares ticagrelor taken at a lower dose versus regular aspirin to help prevent future heart attacks in people who recently had a stent placed after acute coronary syndrome. You may qualify if you’re considered “high risk” for new blockages or clots and can take dual anti-platelet therapy for 12 months.
This trial tests whether a lower dose of the blood thinner ticagrelor works better than clopidogrel in people with stable coronary artery disease who are getting a planned stent. It aims to find which drug is safer and more effective for preventing future heart problems.
This study tests if a single blood thinner (ticagrelor) works well enough after getting a heart stent, instead of the usual two blood thinners. It may simplify your daily medication routine.
This study compares two ways to manage blood thinners after a stent. It tests whether switching from stronger drugs (prasugrel or ticagrelor) to clopidogrel is safe and effective for long-term heart protection.
Hear when a new High Ischemic Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.